India: Mashelkar Committee Withdraws Its Report

Last Updated: 1 March 2007
Article by Manisha Singh

In an unprecedented twist in the legislative process, the Technical Expert Group on Patent Law Issues requested the Government of India to withdraw its Report that was submitted by the Group on December 29, 2006. The Government of India constituted the Expert Group in April 2005 in a follow up of the issues raised in the Parliament during the debate on Patent (Amendment) Bill, 2005. The Government referred two contentious issues to the Group for in-depth analysis and expert opinion and the same formed its terms of reference. The issues were:

  1. whether it would be TRIPS compatible to limit the grant of patent for pharmaceutical substance to ‘new chemical entity’ or to ‘new medical entity’ involving one or more inventive steps; and
  2. whether it would be TRIPS compatible to exclude micro-organisms from patenting.

The Technical Expert Group comprised Dr. R. A. Mashelkar, former Director General of the Council of Scientific and Industrial Research as its chairman and renowned scientists and academicians Prof. Goverdhan Mehta, Prof. Asis Dutta, Prof. N. R. Madhav Menon and Prof. Moolchand Sharma as its members.

In order to come out with a comprehensive Report, the Expert Group adopted a consultative approach and invited views, opinions and inputs from a range of stakeholders including industry players and associations, non-government organizations, Intellectual Property think tanks and attorneys. And in fact a large number of submissions were made to the Group. The Group also studied and submitted in its Report, the patenting practices followed in some leading countries in relation to pharmaceutical derivatives and microorganism. Further the Report stated that in making recommendation to the Government, it was guided by the need for access of affordable medicines to Indian people at large, encouraging innovation by Indian pharma industry, its current capabilities in R&D, and balancing of India’s obligations under international agreements with the wider public interest.

It took more than one and half year to the Group to interact with various stakeholders and to conduct a critical examination of technical and legal issues involved in the study and finally in December 2006, the Group formalized its pointed conclusions to the term of reference that:

  1. it would not be TRIPS compliant to limit granting of patents for pharmaceutical substance to New Chemical Entities only.
  2. it would not be TRIPS compliant to exclude micro organism per se from patenting.

In addition to the above conclusion, the Group recognized the need and importance of (i) distinguishing "evergreening" from "incremental innovation" and encouraging the later, (ii) making provisions for availability of drugs at affordable prices to the people of India and (iii) preventing grant of frivolous patents leading to "evergreening". Accordingly, the Group recommended, "detailed guidelines should be formulated and rigorously followed by the Indian Patent Office for examining the patent application in pharmaceutical sector so that the remotest possibility of granting frivolous patents is eliminated". Interestingly, the Patents Amendment Act came up with a different definition for section 3 (d), pending the Expert Committee report. But the conclusion and recommendation of the Group had favorable overtones for Novartis as they had challenged the constitutional validity of Section 3(d) of the Patent Act, 1970 (as amended in 2005) before the Madras High Court. Amended Section 3 (d) excludes pharmaceutical derivatives from patenting unless they "differ significantly in properties with regard to efficacy".

Incidentally, Dr. Mashelkar submitted the report on the last day in the office of CSIR after completing a long tenure of thirty years. However, upon submission of the Report to the Government in December 2006, criticism followed from several quarters including from the Left Parties, non-governmental organization, public health groups and Indian generic drug industry. Some national dailies even alleged plagiarism stating that the Report contains verbatim reproduction of passages from a Paper written and submitted by Mr. Shamnad Basheer. Mr. Basheer, is a visiting Associate Professor of Intellectual Property Laws at George Washington University Law School. According to news reports and as quoted at his blogsite Mr. Basheer was commissioned by the Intellectual Property Institute (IPI), UK, to produce a paper titled ‘Limiting the Patentablity of Pharmaceutical Inventions and Micro organisms : A TRIPS Compatibility Review.’ On invitation of inputs by the Group, IPI, UK submitted the extracts from Mr. Basheer’s paper and the same is figured in Anexure III of the Report.

It was alleged that one of the most vital aspect of the conclusions in the report in Para 5.10 was verbatim reproduction of the extracts submitted by Mr. Basheer to IPI, UK. The said paragraph states as follows

"It is important to distinguish 'ever-greening' from what is commonly referred to as 'incremental innovation'. While 'ever-greening' refers to an extension of a patent monopoly, achieved by executing trivial and insignificant changes to an already existing patented product, 'incremental innovations' are sequential developments that build on the original patented product and may be of tremendous value in a country like India. Therefore, such incremental developments ought to be encouraged by the Indian patent regime."

Dr. Mashelkar, the Chairman of the Expert Group clarified the situation by stating "After submission of the report, it has been found that there are certain technical inaccuracies in the report that have inadvertently crept in". He further explained that the error could have crept due to drafting lapses by a sub-group. However, he on behalf of the Group took "full responsibility for this unfortunate development" and requested the Government to withdraw the Report. The request for withdrawal of the Report by the Group was made unanimously.

The Group has requested the Government for three months time to reexamine and resubmit the report. It is still uncertain that whether the entire report will be rewritten or only the alleged plagiarized portions would be rephrased. The left parties and the experts on Patent law are however, demanding that the Union Government should reject any proposal from the Group members to rewrite the "plagiarized" Report and has demanded for the appointment of Joint Parliamentary Committee as the issues involved have serious implications.

© Lex Orbis 2007

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions